ZNF217 and hematopoietic and lymphoid cell neoplasm: In non-hematologic cancers, DNA binding of ZNF217 to specific cis-regulatory regions correlates negatively with gene expression, suggesting its function as a transcriptional repressor through interaction with epigenetic regulators such as CoREST, CtBP, LSD1, and EZH2 [33].